The impact of chemotherapy dose density and dose intensity on breast cancer outcomewhat have we learned?

European Journal of Cancer

Volumn 36, Issue SUPPL. 1, 2000, Pages 4-10

  Piccart, M J ^a   Biganzoli, L ^a   Di Leo, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Anthracycline; Breast cancer; Cumulative dose; Cyclophosphamide; Dose density; Dose intensity; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; DRUG ADMINISTRATION; DRUG DOSE; FEMALE; HUMAN; MODEL; PRIORITY JOURNAL; REVIEW; THEORY; TREATMENT OUTCOME;

EID: 0033997960     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00256-7     Document Type: Article

References (21)

1. Fisher B, Redmond CK, Wolmark N. NSABP Investigators. Long-term results from NSABP trials of adjuvant therapy for breast cancer. In Salmon SE, ed. Adjuvant Therapy of Cancer V. Orlando, Florida, Grune & Stratton, 1987, 283-295.
2. Bonadonna G. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989, 7, 1380-1397.
3. Early Breast Cancer Trialists Collaborative Group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988, 3, 1681-1682.
4. Hryniuk W, Bush H. The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2, 1281-1288.
5. Von Hoff DD, Clark GM, Weiss GR, et al. Use of in vitro dose-response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986, 4, 1827-1834.
6. Hryniuk W, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. Natl Cancer Inst Monogr 1986, 1, 87-94.
7. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986, 4, 1162-1170.
8. Hryniuk W. More is better. J Clin Oncol 1988, 6, 1365-1367.
9. Biganzoli L, Piccart MJ. The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 1997, 8, 1177-1182.
10. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997, 15, 1858-1869.
11. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994, 330, 1253-1259.
12. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998, 90, 1205-1211.
13. Thor AD, Berry DA, Budman DR, et al. c-erb-B2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998, 90, 1346-1360.
14. Hudis C, Seidman A, Raptis G, et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996, 23(Suppl. 1), 58-64.
15. Di Leo A, Crown J, Nogaret LM, et al. Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel (AT) in the adjuvant treatment of breast cancer (BC). Eur J Cancer 1998, 34(Suppl. 5), S41 (abstract 166).
16. Piccart MJ. Personal communication, 21st European Society for Medical Oncology Congress, Vienna, 4 November 1996.
17. Bonneterre J, Roché H, Brémond A, et al. On behalf of the French adjuvant study group (FASG). Results of a randomised trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients. Proc Am Soc Clin Oncol 1998, 17, 124a (abstract 473).
18. Henderson IC, Berry D, Demetri G, et al. CALGB, ECOG, SWOG, and NCCTG. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998, 17, 101a (abstract 390a).
19. Brémond A, Kerbrat P, Fumoleau P, et al. Five year follow-up results of a randomised trial testing the role of the dose intensity and duration of chemotherapy in node-positive premenopausal breast cancer patients. Proc Am Soc Clin Oncol 1996, 15, 113 (abstract 199).
20. Therasse P, Tsitsa C, Sahmound T, et al. Neo-adjuvant chemotherapy in locally advanced breast cancer: FEC (5-FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim). An EORTC-NCIC-SAKK study. Preliminary results of dose intensity. Eur J Cancer 1995, 31A(Suppl. 5), 581 (abstract 372).
21. Venturini M, Del-Mastro L. More on dose-intensity of anthracyclines in breast cancer. Ann Oncol 1998, 9, 461.